MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer.

MLA

Ghalavand, Majdedin, et al. “MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-Mesenchymal Transition and MTOR Signaling Pathway in Triple Negative Breast Cancer.” Iranian Journal of Allergy, Asthma, and Immunology, vol. 22, no. 1, Feb. 2023, pp. 46–61. EBSCOhost, https://doi.org/10.18502/ijaai.v22i1.12006.

APA

Ghalavand, M., Dorostkar, R., Borna, H., Mohammadi-Yeganeh, S., & Hashemi, S. M. (2023). MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer. Iranian Journal of Allergy, Asthma, and Immunology, 22(1), 46–61. https://doi.org/10.18502/ijaai.v22i1.12006

Chicago

Ghalavand, Majdedin, Ruhollah Dorostkar, Hojat Borna, Samira Mohammadi-Yeganeh, and Seyed Mahmood Hashemi. 2023. “MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-Mesenchymal Transition and MTOR Signaling Pathway in Triple Negative Breast Cancer.” Iranian Journal of Allergy, Asthma, and Immunology 22 (1): 46–61. doi:10.18502/ijaai.v22i1.12006.